IntoCell, Inc. (KOSDAQ:287840)
South Korea · Delayed Price · Currency is KRW 17,600
-590 (-3.24%)
At close: Sep 3, 2026
IntoCell Revenue
IntoCell had revenue of 760.30M KRW in the quarter ending June 30, 2026, with 1,829.58% growth. This brings the company's revenue in the last twelve months to 3.19B, up 156.17% year-over-year. In the year 2025, IntoCell had annual revenue of 2.30B, down -20.86%.
Revenue (ttm)
3.19B
Revenue Growth
+156.17%
P/S Ratio
85.93
Revenue / Employee
n/a
Employees
n/a
Market Cap
274.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.30B | -605.91M | -20.86% |
| Dec 31, 2024 | 2.91B | 1.29B | 79.72% |
| Dec 31, 2023 | 1.62B | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 140.03M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 124.81B |
| ROKIT Healthcare | 32.81B |
| Genome & Company | 24.46B |
| NIBEC | 22.60B |
| S.Biomedics | 16.49B |
| curacle co.,ltd. | 8.24B |
| Inventage Lab | 3.16B |
| Kangstem Biotech | 3.03B |